Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer

In an assessment of immune cell subsets, researchers used molecular profiling to elucidate effects on antitumor immunity with results suggesting that administering trilaciclib prior to gemcitabine plus carboplatin (GCb) versus GCb alone may modulate the composition and response of immune cell subsets to triple-negative breast cancer (TNBC), as well as enhanced T-cell activation and improved overall survival of patients with metastatic TNBC.